knowledge -WSS

knowledge

author：comprehensive 2025-10-01 15:29:21 - browse：51

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

knowledge

focus

WSS

Eyeing GLP

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Eyeing GLP

Congress considering partial increase for doctor pay in Medicare

Digital health: a case of mistaken identity

As a primary care physician, here's how I hope to partner with AI

hotspot

knowledge

knowledge

Medical records are filled with copy

Cue Health, Covid

Peter Hotez and the public health issue of online harassment

Study gives hint on South Asians’ higher risk of cardiovascular disease

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biogen joins immunology wave with $1.15 billion acquisition of HI

Continuity nursing helped my family in our darkest PICU moments

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Hepatitis C has a cure — but many Americans still lack access to it

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

explore

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Ebola vaccine can save some who are already sick, per new study

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Biogen joins immunology wave with $1.15 billion acquisition of HI

Study gives hint on South Asians’ higher risk of cardiovascular disease

Latigo launches with $135 million for Vertex

knowledge

explore

focus

focus